Nanomedicine is an emerging field with a large potential for developing public welfare and economic growth. Critical issues for bringing up this potential in Europe concern especially the maturity of the economic players and their capability to move effectively innovation from knowledge to industrial technology and to clinical and public health applications. Industrial players need therefore to collaborate closer with scientific partners and with clinicians. The second issue is the ability of companies to establish multidisciplinary networks with the research and the clinician communities, increasing their efforts towards biological preclinical and clinical validations. This will shorten the delay for patients to benefit from the innovation and increase the competitiveness of European actors. Therefore EuroNanoMed targets the creation of a mechanism to support trans-national collaborative RTD projects between academic laboratories, companies, especially SME’s, and clinicians/public health setting, in the field of Nanomedicine, using a bottom up approach. In consequence, EuroNaNoMed will develop coordinated European-wide programmes based on common joint transnational calls and funding. The thematic of these two calls will focus on the strategic research priorities of the European technology platform “Nanomedicine”: diagnostics, targeted delivery and regenerative medicine. EuroNanoMed achieves an effective critical mass: the 19 participating national/regional programmes expect to dedicate significant budget to the calls, approximately 15-20% of the sum of their national/regional Nanomedicine budgets. The Long Term Vision of EuroNanoMed is the design of a European-wide integrated programme with a coordinated funding. Potential scenario for implementation will be suggested.